Ref: MHL/Sec&Legal/2024-25/25

To,

BSE Limited Scrip Code: 542650 National Stock Exchange of India Ltd

Date: July 09, 2024

Scrip Symbol: METROPOLIS

Dear Sir/ Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has provided a business update for the quarter ended June 30, 2024.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended June 30, 2024. A detailed information update will follow once the Board of Directors approve the financial results for O1FY25.

Over the past 12 to 18 months, despite competition from hospitals, organized players and health-tech Companies, Company has focused on its strengths and delivered strong growth. The Company is able to increase its share in the B2C segments on account of strong brand trust, industry-leading testing capabilities, and enhanced efforts in curating the wellness portfolio. Even in the B2B segment, Company has focused on enhancing services and value adds to customers and achieved robust double-digit revenue growth.

Despite Q1 being a historically weak quarter for diagnostics Company for west India, which is the largest contributing region, the Company experienced strong revenue growth for Q1FY25 supported majorly by increase in volumes for patients and tests across segments. This was driven mostly by existing networks of centers and partly by new networks.

Considering ongoing investments in new lab expansion, technology enhancement and brand building, Company was able to increase its margins on a Y-o-Y basis due to operating leverage via higher B2C business

Please find below key highlights of Q1FY25:


- Revenues grew by ~13% for Q1FY25 on Y-o-Y basis.
- Revenue growth was driven by patient volume growth approximately @ ~7% and test volume growth @ ~9.5% Y-o-Y for Q1FY25.
- Truhealth wellness and bundling segment is the fastest-growing part of the Company.
- B2C revenues grew at ~18% Y-o-Y for Q1FY25.
- Company is debt free & having cash reserves of INR ~140 crores as on June 30, 2024.

The Quarterly Business Update is on a Consolidated basis. The financial results of Q1FY25 is subject to review by Auditors.

Thanking you, Yours faithfully,

For Metropolis Healthcare Limited

Kamlesh C Kulkarni Head – Legal & Secretarial



BLOOD TESTS • DIAGNOSTICS • WELLNESS

Metropolis Healthcare Limited

Registered Office: 4th Floor, East Wing, Plot-254 B, Nirlon House, Dr. Annie Besant Road, Worli, Mumbai - 400030, Maharashtra, India.

Corporate Office & Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com Website: www.metropolisindia.com